⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 14, 2025Journal of the American Academy of DermatologyOpen Access

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study

Lawrence F. Eichenfield Linda Stein Gold Eric L. Simpson Andrea L. Zaenglein April W. Armstrong Megha M. Tollefson Weily Soong Lara Wine Lee Alim R Devani Seth Forman Dareen Siri Howard Kallender Brett Angel Qian Li Xuejun Chen Amy S. Paller

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Ruxolitinib cream provided superior improvements versus vehicle in AD signs and symptoms in children with mild-to-moderate AD and was well tolerated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Eichenfield et al. (2025) studied this question.

synapsesocial.com/papers/69dc2a648bac30e30e9f536c https://doi.org/10.1016/j.jaad.2025.05.1385

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1703 - Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study2024
2Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trialRCT · 2026
3Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies2024 · 10 citations
4Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis.2025 · 1 citations
5Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review and meta‐analysisMeta-Analysis · 2026